The impact of COVID-19 infection on idiopathic pulmonary fibrosis mortality: a systematic review and meta-analysis
Open Access
- 15 October 2024
- journal article
- review article
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 95 (4)
Abstract
COVID-19 has a negative impact on the survival of respiratory patients, especially those with interstitial lung disease. This review aims to better understand the effect of COVID-19 on patients with idiopathic pulmonary fibrosis (IPF). A systematic search of MEDLINE, PubMed, Embase, and Scopus performed from December 2019 up to July 2024 identified relevant studies. Eligibility criteria included English language, sample size ≥10 patients, COVID-19 infection, and outcome measures. Two independent reviewers assessed studies using the Newcastle-Ottawa Scale for bias and extracted data. Meta-analysis employed a random-effects model, and the Grading of Recommendations Assessment, Development and Evaluation assessed evidence quality. Outcomes considered were hospitalization, intensive care unit admission, and mortality. Of the 1541 initially identified articles, 6 high-quality studies were included. Meta-analysis revealed a 34% mortality rate [95% confidence interval (CI): 21-48%], 36% hospitalization rate (95% CI: 10-75%), and 31% intensive care unit admission rate (95% CI: 7-71%) among IPF patients with COVID-19. The certainty of evidence was low or very low due to publication bias and heterogeneity. This study underscores the elevated risk of hospitalization and death in IPF patients with COVID-19, emphasizing the vulnerability of this population. Prompt and tailored care is crucial to mitigate the impact of COVID-19 on IPF patients, necessitating proactive measures, vaccination, and comprehensive management.Keywords
This publication has 42 references indexed in Scilit:
- Risk factors associated with COVID‐19 pneumonia in Chinese patients with pre‐existing interstitial lung disease during the SARS‐CoV‐2 pandemicJournal of Medical Virology, 2023
- Impact of COVID-19 Infection on Patients with Preexisting Interstitial Lung Disease: A Spanish Multicentre StudyArchivos de Bronconeumología, 2023
- Frailty and long-COVID: is COVID-19 responsible for a transition in frailty status among older adults who survived hospitalization for COVID-19?Aging Clinical and Experimental Research, 2022
- Pre-existing interstitial lung disease in patients with coronavirus disease 2019: A meta-analysisInternational Immunopharmacology, 2021
- COVID-19 and acute exacerbation of interstitial lung diseaseRespiratory Investigation, 2021
- Access to intensive care in 14 European countries: a spatial analysis of intensive care need and capacity in the light of COVID-19Intensive Care Medicine, 2020
- Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 PandemicChest, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventionsJournal of Clinical Epidemiology, 2020
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaborationJournal of Clinical Epidemiology, 2009